Inhibición de JAK como una estrategia terapéutica para Enfermedades Inmunes e Inflamatorias
Nat Rev Drug Discov 2017;16:843–62 DOI: 10.1038/nrd.2017.201
Janus kinases (JAKs) are essential mediators of downstream signaling pathways in many inflammatory and autoimmune diseases. This review summarizes current clinical data on first- and second-generation JAK inhibitors (jakinibs) and discusses their use for the treatment of immune and inflammatory conditions.First generation jakinibs such as tofacitinib, baricitinib, and ruxolitinib, non-selectively inhibit JAK-dependent pro-inflammatory cytokines, which are major contributors to immunopathology. T...